This strong performance reflects our revenue growth higher investment in sales and marketing to support our biosimilar and specialty brands, offset by tight expense management across the remaining operations.

May 5, 2023 / CFO / receipt, needs a key / Tasos Conideras, CFO | earnings call 2023-05-05 | transcript 9a77c713-5511-401c-b60f-61812044d3da | chars 15818-16026 | segment 16